数据
资源
版本对比
免费注册
预约演示
免费注册
Bausch + Lomb
Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting
2023-10-04
·
BioSpace
临床结果
临床3期
Presentations Will Feature Blink® Triple Care Lubricating Dry Eye Drops,
MIEBO
™ (
perfluorohexyloctane ophthalmic solution
) and
Bausch + Lomb
INFUSE® Multifocal Lenses Company Will Host Seven Educational Events VAUGHAN, Ontario--(BUSINESS WIRE)--
Bausch + Lomb Corporation
(NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced one podium presentation and four poster presentations during the
American Academy of Optometry (AAOpt)
annual meeting, which will take place in New Orleans Oct. 11-14, 2023. The podium presentation will highlight the results of a prospective, multi-center study that evaluated key clinical
dry eye disease (DED)
findings in patients using Blink Triple Care Dry Eye Lubricating Eye Drops.
Bausch + Lomb
acquired the Blink brand of eye drops for dry eyes and contacts from
Johnson & Johnson Vision
earlier this year. Two poster presentations will include data on the newly launched
MIEBO
prescription eye drops, including an evaluation of the distribution and retention of
MIEBO
on the human eye and an analysis of the effect of
MIEBO
on fluorescein staining across all regions of the cornea. Additionally, two posters will feature data on
Bausch + Lomb
INFUSE Multifocal silicone hydrogel daily disposable contact lenses, which launched in June, including an evaluation of the lens’ clinical performance and an assessment of patient responses to the lens.
Bausch + Lomb
will also host several educational events during the meeting featuring MIEBO eye drops, the new LUMIFY EYE ILLUMINATIONS™ product line,
LOTEMAX
® SM (
loteprednol etabonate
ophthalmic gel) 0.38% and
VYZULTA
® (
latanoprostene
bunod ophthalmic solution) 0.024%. Another educational event will highlight practical patient cases using products from across the company’s consumer, vision care and pharmaceutical portfolios. The
Bausch + Lomb
schedule at AAOpt: Podium Presentation “Clinical Dry Eye Findings in Patients Using a Novel Lipid-Containing Eye Drop.” Joshi et al. Poster Presentations “Clinical Performance of a Novel Daily Disposable Silicone Hydrogel Multifocal Contact Lens.” Schafer et al. “
Perfluorohexyloctane
, an Eye Drop for
Dry Eye Disease
, Reduces Corneal Staining Across All Regions of the Cornea.” Fahmy et al. “Presbyopic Patient Assessment of a New Daily Disposable Silicone Hydrogel Multifocal Contact Lens.” Rah et al. “Visualization of
MIEBO
, an Eye Drop for
Dry Eye Disease
, on the Human Ocular Surface Using Infrared Emisivity.” Borchman et al. Featured Educational Events Wednesday, October 11 “Industry Innovation Lunch and Learn” 12-12:55 p.m. CT at the Ernest N. Morial Convention Center (900 Convention Center Blvd., New Orleans; Room R06, second floor) Gina Wesley, O.D., John Womack, O.D., and Doug DeVries, O.D., will share practical patient cases using products from across the
Bausch + Lomb
consumer, vision care and pharmaceutical portfolios. “Showcasing
Inflammation
and IOP Control” 6:45 p.m. CT at Palace Café (605 Canal Street, New Orleans; room Fleur de Lis) Michael Chaglasian, O.D., and Nora Cothran, O.D. will discuss the benefits of using
LOTEMAX
® SM (
loteprednol etabonate
ophthalmic gel), 0.38%, and
VYZULTA
® (
latanoprostene
bunod ophthalmic solution), 0.024%. Register in advance. Thursday, October 12 “Introducing New LUMIFY EYE ILLUMINATIONS” 8:00-8:45 a.m. CT at Hilton New Orleans Riverside (Two Poydras Street, New Orleans; room Royal) Join Gina Wesley, O.D., to discover LUMIFY EYE ILLUMINATIONS, a new specialty eye care line. “Innovations in
Inflammation
and IOP Control” 8:00-8:45 a.m. CT at Hilton New Orleans Riverside (Two Poydras Street, New Orleans; room Camp) Derek Cunningham, O.D., will discuss the benefits of using
LOTEMAX
® SM (
loteprednol etabonate
ophthalmic gel), 0.38%, and
VYZULTA
® (
latanoprostene
bunod ophthalmic solution), 0.024%. “Fighting the Battle in the Rx Treatment of
Evaporative Dry Eye Disease
: Introducing
MIEBO
(
Perfluorohexyloctane Ophthalmic Solution
)” 6:00 p.m. CT at the National World War II Museum (1043 Magazine Street, US Freedom Pavilion, New Orleans) Learn about
MIEBO
, the first and only prescription eye drop that directly targets tear evaporation, as well as the results of the
MIEBO
pivotal phase 3 studies. Register in advance. Friday, October 13 “
MIEBO
(
perfluorohexyloctane ophthalmic solution
): A Newly Approved Product” 8:00-8:45 a.m. CT at Hilton New Orleans Riverside Hotel (Two Poydras Street, New Orleans; room Canal) Tear evaporation is the leading cause of
dry eye disease
. Join James Deom, O.D., to learn more about
MIEBO
, the first and only prescription eye drop that directly addresses tear evaporation. “A New Orleans Nightcap with LUMIFY EYE ILLUMINATIONS” 8:30-10:30 p.m. CT at the Gallery Venue (755 Tchoupitoulas Street, New Orleans) Celebrate the launch of LUMIFY EYE ILLUMINATIONS and learn about these new clinically proven products from Selina McGee, O.D. Register in advance. Important Safety Information for
MIEBO
INDICATION
MIEBO
™ (
perfluorohexyloctane ophthalmic solution
) is used to treat the signs and symptoms of
dry eye disease
. IMPORTANT SAFETY INFORMATION Patients should remove contact lenses before using
MIEBO
™ and wait for at least 30 minutes before reinserting. It is important for patients to use
MIEBO
exactly as prescribed. It is not known if
MIEBO
™ is safe and effective in children under the age of 18. The most common eye side effect seen in studies was blurred vision (1% to 3 % of patients reported blurred vision and
eye redness
). Click here for full Prescribing Information for
MIEBO
. Important Safety Information for
LOTEMAX SM
INDICATION
LOTEMAX SM
(
loteprednol etabonate
ophthalmic gel) 0.38% is a
corticosteroid
indicated for the treatment of
post-operative inflammation
and
pain
following ocular surgery. IMPORTANT SAFETY INFORMATION
LOTEMAX SM
, as with other
ophthalmic corticosteroids
, is contraindicated in most
viral diseases
of the cornea and conjunctiva including
epithelial herpes simplex keratitis (dendritic keratitis)
,
vaccinia
, and
varicella
, and also in
mycobacterial infection
of the eye and
fungal diseases
of ocular structures. Prolonged use of corticosteroids may result in
glaucoma
with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of
glaucoma
. If
LOTEMAX SM
is used for 10 days or longer, IOP should be monitored. Use of corticosteroids may result in posterior subcapsular cataract formation. The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those with diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining. Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of
secondary ocular infections
. In acute purulent conditions, steroids may mask
infection
or enhance existing
infections
. Employment of a
corticosteroid
medication in the treatment of patients with a history of
herpes simplex
requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many
viral infections
of the eye (including
herpes simplex
).
Fungal infections
of the cornea are particularly prone to develop coincidentally with long-term local
steroid
application. Fungus invasion must be considered in any
persistent corneal ulceration
where a
steroid
has been used or is in use. Fungal cultures should be taken when appropriate. Contact lenses should not be worn when the eyes are inflamed. There were no treatment-emergent adverse drug reactions that occurred in more than 1% of subjects in the three times daily group compared to vehicle. Click here for full Prescribing Information for
LOTEMAX SM
. Important Safety Information for
VYZULTA
INDICATION
VYZULTA
(
latanoprostene bunod ophthalmic solution
) 0.024% is indicated for the reduction of intraocular pressure (IOP) in patients with
open-angle glaucoma
or
ocular hypertension
. IMPORTANT SAFETY INFORMATION Increased pigmentation of the iris and periorbital tissue (eyelid) can occur. Iris pigmentation is likely to be permanent Gradual changes to eyelashes, including increased length, increased thickness, and number of eyelashes, may occur. These changes are usually reversible upon treatment discontinuation Use with caution in patients with a history of
intraocular inflammation
(
iritis
/
uveitis
).
VYZULTA
should generally not be used in patients with
active intraocular inflammation
Macular edema
, including
cystoid macular edema
, has been reported during treatment with
prostaglandin analogs
. Use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for
macular edema
There have been reports of
bacterial keratitis
associated with the use of multiple-dose containers of topical ophthalmic products that were inadvertently contaminated by patients Contact lenses should be removed prior to the administration of
VYZULTA
and may be reinserted 15 minutes after administration Most common ocular adverse reactions with incidence ≥2% are
conjunctival hyperemia
(6%),
eye irritation
(4%), eye pain (3%), and instillation site pain (2%) Please click here for full Prescribing Information. Patients are encouraged to report negative side effects of these prescription drugs to the FDA. Visit or call 1-800-FDA-1088. About
Bausch + Lomb
Bausch + Lomb
is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from the moment of birth through every phase of life. Its comprehensive portfolio of more than 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853,
Bausch + Lomb
has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries.
Bausch + Lomb
is headquartered in Vaughan, Ontario with corporate offices in Bridgewater, New Jersey. For more information, visit and connect with us on Twitter, LinkedIn, Facebook and Instagram. Forward-looking Statements This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “hopes,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in
Bausch + Lomb
’s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof.
Bausch + Lomb
undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. © 2023
Bausch + Lomb
. MTB.0285.USA.23
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Bausch + Lomb Corp.
Bausch & Lomb, Inc.
American Academy of Optometry
[+1]
适应症
干眼症
干眼综合征
炎症
[+22]
靶点
-
药物
全氟己基辛烷
氯替泼诺
Latanoprostene Bunod
[+4]
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
热门报告
THR-β 激动剂药物进展及专利调研报告
智慧芽生物医药
2024年2月全球首批及特殊审评药物报告
智慧芽生物医药
TYK2抑制剂药物研发及专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务